During the 18 months Jeremy Levin served as president and CEO, Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) disclosed only six smallish pipeline-building deals. By comparison, Levin executed four acquisitions worth about $4 billion and at least 15 pipeline-building licensing deals during the four years he was SVP of strategy, alliances and transactions at Bristol-Myers Squibb Co. (NYSE:BMY). Most recent deal at top. (A) Huntexil had completed a Phase III trial, but Teva planned to resume development